Contineum Therapeutics, Inc. Class A (CTNM) Stock Forecast, Price Target & Predictions
CTNM Stock Forecast
Contineum Therapeutics, Inc. Class A stock forecast is as follows: an average price target of $30.33 (represents a 128.05% upside from CTNM’s last price of $13.30) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
CTNM Price Target
The average price target for Contineum Therapeutics, Inc. Class A (CTNM) is $30.33 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $32.00 to $29.00. This represents a potential 128.05% upside from CTNM's last price of $13.30.
CTNM Analyst Ratings
According to 2 Wall Street analysts, Contineum Therapeutics, Inc. Class A's rating consensus is 'Buy'. The analyst rating breakdown for CTNM stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Contineum Therapeutics, Inc. Class A Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 21, 2024 | Joel Beatty | Robert W. Baird | $32.00 | $16.07 | 99.13% | 140.60% |
| Apr 30, 2024 | Brian Abrahams | RBC Capital | $30.00 | $16.00 | 87.50% | 125.56% |
| Apr 30, 2024 | Paul Matteis | Stifel Nicolaus | $29.00 | $16.00 | 81.25% | 118.05% |
The latest Contineum Therapeutics, Inc. Class A stock forecast, released on Oct 21, 2024 by Joel Beatty from Robert W. Baird, set a price target of $32.00, which represents a 99.13% increase from the stock price at the time of the forecast ($16.07), and a 140.60% increase from CTNM last price ($13.30).
Contineum Therapeutics, Inc. Class A Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 1 | 3 |
| Avg Price Target | $32.00 | $32.00 | $30.33 |
| Last Closing Price | $13.30 | $13.30 | $13.30 |
| Upside/Downside | 140.60% | 140.60% | 128.05% |
In the current month, the average price target of Contineum Therapeutics, Inc. Class A stock is $32.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 140.60% increase as opposed to Contineum Therapeutics, Inc. Class A's last price of $13.30. This month's average price target is down 0.00% compared to last quarter, and up 5.51% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Apr 30, 2024 | Morgan Stanley | - | Overweight | Initialise |
| Apr 30, 2024 | RBC Capital | - | Outperform | Initialise |
Contineum Therapeutics, Inc. Class A's last stock rating was published by RBC Capital on Aug 14, 2024. The company gave CTNM a "Outperform" rating, the same as its previous rate.
Contineum Therapeutics, Inc. Class A Financial Forecast
Contineum Therapeutics, Inc. Class A Revenue Forecast
| Revenue |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| # Analysts |
| Surprise % |
Contineum Therapeutics, Inc. Class A's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CTNM's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Contineum Therapeutics, Inc. Class A EBITDA Forecast
| # Analysts |
| EBITDA |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
undefined analysts predict CTNM's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Contineum Therapeutics, Inc. Class A's previous annual EBITDA (undefined) of $NaN.
Contineum Therapeutics, Inc. Class A Net Income Forecast
| # Analysts |
| Net Income |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
Contineum Therapeutics, Inc. Class A's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CTNM's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Contineum Therapeutics, Inc. Class A SG&A Forecast
| # Analysts |
| SG&A |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
Contineum Therapeutics, Inc. Class A's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CTNM last annual SG&A of $NaN (undefined).
Contineum Therapeutics, Inc. Class A EPS Forecast
| # Analysts |
| EPS |
| Avg Forecast |
| High Forecast |
| Low Forecast |
| Surprise % |
According to undefined Wall Street analysts, Contineum Therapeutics, Inc. Class A's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CTNM previous annual EPS of $NaN (undefined).